Pathos AI, Inc.
Category: AI in Healthcare
An AI-enabled biotechnology company re-engineering drug development using machine learning and real-world clinical and molecular data to advance precision oncology therapeutics. Pathos AI, Inc. was founded in 2022. The company is led by Iker Huerga. Based in Chicago, IL, USA. Team size: 51-200. Total funding raised: ~$427M total (all rounds). Latest round: Series D ($365M, May 2025 at ~$1.6B valuation - unicorn status). Key investors include New Enterprise Associates (NEA), Revolution Growth, General Catalyst, Deerfield Management, ARCH Venture Partners, Tempus Labs.
- Founded
- 2022
- Headquarters
- Chicago, IL, USA
- Team size
- 51-200
- Total funding
- ~$427M total (all rounds)
Value proposition
Leveraging proprietary AI and extensive clinical data to accurately identify patient subpopulations, acquire or license targeted clinical-stage therapies, and de-risk the drug development process in precision oncology.
Products and solutions
PathOS™ Platform: Proprietary AI platform integrating multi-modal patient data for target identification and patient stratification., P-300 (FT-7051): Licensed clinical-stage CBP/p300 inhibitor targeting specific cancer types.
Unique value
Integrates large-scale real-world patient data with a proprietary AI platform to identify unique biological mechanisms and patient subtypes, subsequently acquiring or licensing clinical-stage assets for focused development.
Target customer
Biopharmaceutical companies (for strategic partnerships and co-development) and cancer patients as ultimate beneficiaries
Industries served
Biotechnology, Pharmaceuticals, Healthcare, Oncology
Technology advantage
Access to extensive clinical and molecular datasets, a robust in-house AI-driven PathOS™ platform, and strategic leadership links originating from Tempus Labs.
How they differentiate
Focuses on the identification and acquisition/licensing of existing clinical-stage assets through precise AI-driven patient stratification rather than pursuing a solely de novo drug discovery approach.
Main competitors
Tempus Labs, Recursion Pharmaceuticals, Exscientia, BenevolentAI, Insitro
Key partnerships
Tempus Labs (Strategic data and expertise partnership), Novo Nordisk (Licensing agreement for P-300/FT-7051), Various biopharmaceutical companies (in collaborative drug development models)
Notable customers
Biopharmaceutical companies, Novo Nordisk (licensing partner)
Major milestones
Spun out from Tempus Labs in 2022 Closed Series A ($15M, Nov 2022) Closed Series B ($35M, Apr 2023) Licensed P-300/FT-7051 from Novo Nordisk (May 2023) Closed Series C ($62M, Oct 2024) Acquired multiple clinical-stage precision oncology assets
Growth metrics
Not publicly disclosed; however, successive funding rounds and asset acquisitions indicate robust growth.
Market positioning
A clinical-stage, precision oncology company that distinguishes itself with a hybrid model of data-driven asset acquisition.
Geographic focus
Primarily United States
Patents and IP
Pending patent filings covering proprietary algorithms and platform components.
About Iker Huerga
Iker Huerga has over 20 years of experience in applying Data Science and Artificial Intelligence to oncology drug development. He was previously the Chief Data Scientist for Oncology R&D at AstraZeneca and an Executive Vice President at Tempus Labs. He is also a serial biotech entrepreneur, having founded three oncology companies with two successful exits.
Official website: https://pathos.com/